Insider Buying: Coleman N. Lannum III Purchases 1,736 Shares of Covidien plc Stock (COV)
Covidien plc (NYSE:COV) VP Coleman N. Lannum III purchased 1,736 shares of the company’s stock in a transaction that occurred on Tuesday, August 26th. The shares were purchased at an average cost of $87.46 per share, with a total value of $151,830.56. Following the completion of the purchase, the vice president now directly owns 13,605 shares in the company, valued at approximately $1,189,893. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of Covidien plc in a research note on Monday, July 28th. They now have a $101.00 price target on the stock, up previously from $81.00. Separately, analysts at Leerink Swann raised their price target on shares of Covidien plc from $93.00 to $95.00 in a research note on Monday, July 28th. They now have a “market perform” rating on the stock. Finally, analysts at RBC Capital raised their price target on shares of Covidien plc from $71.00 to $95.00 in a research note on Monday, July 28th. Eleven analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Covidien plc has an average rating of “Hold” and a consensus target price of $87.54.
Shares of Covidien plc (NYSE:COV) traded down 0.30% on Wednesday, hitting $87.08. The stock had a trading volume of 1,813,096 shares. Covidien plc has a one year low of $59.17 and a one year high of $92.68. The stock has a 50-day moving average of $87.84 and a 200-day moving average of $77.70. The company has a market cap of $39.339 billion and a price-to-earnings ratio of 26.35.
Covidien plc (NYSE:COV) last released its earnings data on Friday, July 25th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.04. The company had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the previous year, the company posted $0.91 earnings per share. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, analysts predict that Covidien plc will post $4.02 earnings per share for the current fiscal year.
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.
Receive News & Ratings for Covidien plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covidien plc and related companies with Analyst Ratings Network's FREE daily email newsletter.